Genedata Webinar: Automating NGS Workflows for Biopharma

Every BioPharma leader knows this moment: Years of development. Billions invested. Then Phase III safety signals appear — and the entire program collapses. It’s not rare. 40% of late-stage failures are tied to safety issues that could have been detected earlier. The problem isn’t innovation. It’s visibility. Traditional monitoring only catches what’s obvious. By then, it’s too late. At Hextropian Systems, we take a different approach. Our neuro-symbolic AI platform analyzes preclinical and early trial data to: - Detect hidden biomarker patterns linked to future adverse events - Predict safety signals long before Phase III - Provide audit-grade explanations regulators and boards can trust The result? Programs that advance with confidence, reduced late-stage failures, and billions saved. Because in BioPharma, the most expensive risks are the ones you don’t see coming. Learn how predictive safety intelligence changes the game → hextropian.ai 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐲𝐨𝐮𝐫 𝐝𝐞𝐦𝐨 𝐭𝐨𝐝𝐚𝐲. #Biopharma #DrugDevelopment #ClinicalTrials #PredictiveSafety #RegulatoryCompliance #PharmaInnovation #RiskPrevention #AuditReady #Hextropian

Scaling breakthroughs is easy. Scaling them reproducibly? That’s where the real work begins. Labs developing cell/gene therapies must build in consistency, GMP alignment, and robust analytics before they move to large-scale production. Sean Manarguez highlights how early donor variability screening, closed systems, and cross-functional alignment move the needle. Dive into the details — and see how your lab can stay ahead: http://bit.ly/4pD5Mri

New Data Set: GDPsm1.2 Microsomal Stability Now Available We're expanding the GDPsm1 ADME dataset series with the release of GDPsm1.2, focused on microsomal stability, a key Tier 1 assay, built using our automated lab infrastructure. Access it now: https://lnkd.in/graFEXRg The GDPsm1 series profiles 320 compounds from the LOPAC 1280 library across foundational ADME assays. ▪️ GDPsm1.1: Kinetic solubility ▪️ GDPsm1.2: Microsomal stability The GDPsm1 series is part of our commitment to provide high-quality, model-ready biological data at scale enabling faster iteration and better predictive modeling as drug discovery shifts toward AI-driven approaches. Find Ginkgo Datapoints at #DOT this week at Booth #422 or at the poster session to learn more about our platform. More information in our blog post: https://lnkd.in/eED6C9FA 

Ginkgo Datapoints has released GDPsm1.2, the newest installment in the GDPsm1 series. Part of a broader initiative to accelerate AI in drug discovery, GDPsm1.2 delivers model-ready ADME data on a 320-compound subset of LOPAC 1280, now available for open access: https://lnkd.in/graFEXRg At Ginkgo, we believe that scaling high-quality experimental data is critical to unlocking the next wave of innovation in life sciences. That’s why Ginkgo Datapoints serves as an automated CRO partner for the ML-driven future of drug development. Catch the Datapoints team this week at #DOT 2025, Booth #422. Learn more in their blog post: https://lnkd.in/eED6C9FA

We asked experts in biotech: what are the biggest untapped opportunities in drug discovery? From smarter clinical trial designs to multiomic analysis, these insights reveal how therapies could reach patients faster, more effectively, and more ethically. See their responses, here: https://bit.ly/4o3d2vh

What makes Clarivate’s Knowledge Graphs a game-changer for pharma and life sciences?    At Clarivate Consulting, our KGs go beyond visualization—connecting curated data from trusted sources like Cortellis Drug Discovery Intelligence (CDDI) and Metabase to uncover insights across genetics, disease, and drug development. With advanced modeling and seamless integration, we empower smarter decisions in drug discovery and personalized medicine. Explore the unique features here: https://lnkd.in/gQUdVg3C   #KnowledgeGraph #Pharma #Innovation #LifeSciences #Clarivate #Consulting

Unlock the 𝐟𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐛𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 with insights from Kean Woodmansey, Senior Product Manager, Echo® MS+. The Echo® MS+ system combined with the ZenoTOF 7600 system leverages acoustic ejection mass spectrometry to transform drug discovery workflows. This platform accelerates assay turnaround times, optimizes buffer conditions, integrates seamlessly with automation, and advances data processing—all while maintaining exceptional analytical quality across diverse applications. For decision-makers and researchers aiming to enhance biomarker quantitation and expedite therapeutic development, this technology offers an unmatched balance of speed and precision. 𝑬𝒙𝒑𝒍𝒐𝒓𝒆 𝒉𝒐𝒘 𝒚𝒐𝒖𝒓 𝒍𝒂𝒃 𝒄𝒂𝒏 𝒃𝒆𝒏𝒆𝒇𝒊𝒕 𝒇𝒓𝒐𝒎 𝒕𝒉𝒊𝒔 𝒕𝒓𝒂𝒏𝒔𝒇𝒐𝒓𝒎𝒂𝒕𝒊𝒗𝒆 𝒊𝒏𝒏𝒐𝒗𝒂𝒕𝒊𝒐𝒏 𝒕𝒐𝒅𝒂𝒚. 🔗 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫 𝐦𝐨𝐫𝐞: https://lnkd.in/gcm3zk-8 #BiomarkerDiscovery #MassSpectrometry #DrugDiscovery #PharmaceuticalResearch #HighThroughputScreening #LabelFreeAnalysis #AutomationInPharma #ProteinQuantitation #PeptideAnalysis #DataDrivenDecisions #AnalyticalChemistry #PharmaInnovation #ZenoTOF7600 #EchoMSPlus #TherapeuticDevelopment

MindWalk Corp. (formerly ImmunoPrecise Antibodies) (#NASDAQ: #HYFT) is redefining drug discovery through bio-native AI and wet lab innovation. CEO Dr. Jennifer Bath shares how the LensAI™ platform and rebranding strategy position the company as a leader in AI-driven healthcare. Learn more through this interview: https://lnkd.in/gSV7FTbS #AI #AIStocks #HealthCare

Thermo Fisher Scientific has introduced a new laboratory-developed test for post-transplant biopsy assessment designed to improve the detection of #lungtransplant rejection and injury, delivering quantifiable results that may increase diagnostic confidence and guide timely treatment. Read more: https://lnkd.in/dXHhXc9J #ThermoFisherScientific #TransplantDiagnostics #LungTransplant #PrecisionMedicine #HealthcareInnovation #ClinicalDiagnostics #PatientCare #Biotech #MedicalInnovation #PharmaIndustrialIndia

We’re excited to share a new case study from our mRNA Revolution: A new generation of medicine, updated for 2025, featuring Touchlight, a UK-based CDMO reshaping how #DNA is made for advanced therapies. Instead of relying on decades-old fermentation methods, Touchlight uses proprietary enzymatic DNA production to deliver GMP-grade DNA quickly, flexibly, and at scale. Their low-footprint manufacturing facilities and significant investment have made them the world’s largest #DNAmanufacturer by capacity, positioning them as a key partner for the fast-growing advanced therapies market. #UKLifeSciences #NewGenRNA